GlassScriptPhysician profile
Tammy T Jacobs
NPI 1538397518
$1,434.11
in general payments reported to CMS, 2019-2025
18 companies · $870 in 2025
The $870 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $244 · 2024: $320 · 2025: $870.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,362 · Education: $72.21.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,361.90 |
| Education | $72.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $363.03 | 2023-2025 | |
| Ars Pharmaceuticals Operations, INC. | $169.14 | 2025 | Neffy |
| Astrazeneca Pharmaceuticals LP | $109.24 | 2023-2025 | Airsupra, Fasenra, Breztri |
| Organon LLC | $102.61 | 2025 | Vtama |
| Regeneron Healthcare Solutions, INC. | $102.31 | 2024-2025 | Dupixent |
| Pharming Healthcare, INC. | $96.38 | 2023-2025 | Ruconest |
| Amgen INC. | $91.91 | 2023-2025 | Tezspire |
| Glaxosmithkline, LLC. | $71.03 | 2024-2025 | Nucala, Trelegy Ellipta |
| Csl Behring | $55.46 | 2024 | Haegarda, Hizentra |
| Lilly USA, LLC | $50.28 | 2025 | Ebglyss |
| Takeda Pharmaceuticals U.S.A., INC. | $41.23 | 2025 | Cuvitru |
| Biocryst US Sales Co., LLC | $34.39 | 2025 | Orladeyo |
| X4 Pharmaceuticals, INC. | $32.15 | 2024 | Xolremdi |
| Novartis Pharmaceuticals Corporation | $31.67 | 2025 | |
| Ionis Pharmaceuticals, INC. | $27.38 | 2025 | Dawnzera |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $23.03 | 2025 | |
| Azurity Pharmaceuticals, INC. | $18.69 | 2025 | Alvesco |
| Blueprint Medicines Corporation | $14.18 | 2025 | Ayvakit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tammy Jacobs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.